Adjuvant Everolimus Does Not Improve Recurrence-Free Survival Among Patients with Renal Cell Carcinoma
Findings from the EVEREST study
Oncology News
ESMO oncology news aims to keep you up to date with the developments that affect you and your daily practice.
Make sure you check these pages frequently, or sign up to our newsletter! To sign up for ESMO newsletters, create a myESMO account here and select the newsletters you’d like to receive.
1548 results
Niraparib Plus Abiraterone Acetate and Prednisone Improves rPFS and Other Clinically Relevant Outcomes in First-Line Treatment for Patients with mCRPC
Findings from the MAGNITUDE study
HER2 Expression is a Determinant of Sensitivity to Trastuzumab Deruxtecan in Metastatic Breast Cancer, Although Other Mechanisms May Be Involved
Findings from the DAISY study
EMA Recommends Granting a Marketing Authorisation for Tislelizumab
It is indicated for the treatment of adult patients with unresectable, locally advanced or metastatic oesophageal squamous cell carcinoma after prior platinum-based chemotherapy
FDA Approves Quizartinib for Newly Diagnosed Acute Myeloid Leukaemia
FDA also approved LeukoStrat CDx FLT3 Mutation Assay as a companion diagnostic
Camrelizumab Plus Rivoceranib Improves Survival Compared with Sorafenib in First-Line Treatment for Patients with Unresectable Hepatocellular Carcinoma
Findings from the CARES-310 study
Niraparib Maintenance Significantly Reduces the Risk of Disease Progression or Death in a Broad Population of Newly Diagnosed Advanced Ovarian Cancer After Response to First-Line Platinum-Based Chemotherapy
Findings from the phase III PRIME study
Machine Learning Model Provides Superior Performance Over Specialist Interpretations and Could Reliably Predict Metastatic Disease in Most Patients with Pheochromocytomas and Paragangliomas
Findings from the machine learning modelling study
SABR with Immunotherapy Significantly Improves Event-Free Survival in Patients with Newly Diagnosed Early-Stage or Isolated Parenchymal Recurrent Node-Negative NSCLC
Findings from a randomised phase II study
EMA Recommends Granting a Marketing Authorisation for Elacestrant
It is indicated for the treatment of postmenopausal women and men with locally advanced or metastatic ER-positive, HER2-negative breast cancer with ESR1 mutation
Activity and Manageable Toxicity of Pembrolizumab in Some Rare and Ultrarare Sarcomas Refractory or Resistant to Standard Therapy
Findings from the AcSé Pembrolizumab study
Durable Antitumour Activity of Pembrolizumab Plus Lenvatinib in Patients with Previously Untreated Advanced Non-Clear-Cell RCC
Findings from the KEYNOTE-B61 study